Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.97 |
| ▸ | NPC1 | O15118 | 5/20 | 0.97 |
| ▸ | RAB9A | P51151 | 5/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | HPGD | P15428 | 3/20 | 0.97 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | APAF1 | O14727 | 2/20 | 0.55 |
| ▸ | CDC25B | P30305 | 2/20 | 0.55 |
| ▸ | TDP2 | O95551 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31718101 | 1.00 | ALDH1A1 (0.97) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL1536486 | 0.81 | RAB9A (0.65) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4768926 | 0.79 | KDM4E (0.63) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL28460190 | 0.77 | KDM4E (0.61) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11364351 | 0.77 | KDM4E (0.65) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL30595154 | 0.76 | KDM4E (0.60) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL308319 | 0.76 | GSK3B (0.61) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL29470995 | 0.76 | GSK3B (0.61) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL1988750 | 0.75 | KDM4E (0.58) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL22201443 | 0.75 | ALDH1A1 (0.59) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP11 | ALDH1A1 1976/4885NPC1 1843/4885RAB9A 3234/4885 |
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | ALDH1A1 2989/4885NPC1 4578/4885RAB9A 2421/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | ALDH1A1 1071/4885NPC1 4576/4885RAB9A 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.